TROP2 Targeted Tx in Adv NSCLC

CME

Clinical Landscape of TROP-2–Targeted Therapy in Advanced/Metastatic NSCLC

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: June 24, 2024

Expiration: June 23, 2025

Edward B Garon
Edward B Garon, MD, MS

Activity

Progress
1 2
Course Completed

References

  1. Zeng P, Chen M-B, Zhau L-N, et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.
  2. Lombardi P, Filetti M, Falcone R, et al. Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers. 2023;15:1744.
  3. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  4. Shastry M, Jacob S, Rugo HS, et al. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169-177.
  5. Bardia A, Krop I, Meric-Bernstam F, et al. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract P6-10-03.
  6. Yasuda S, Maejima T, Toki T, et al. Evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (-) lung cell lines admixed tumor xenograft mouse models. Presented at: 2023 American Association for Cancer Research Annual Meeting; April 14-19, 2023. Abstract 4893.
  7. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase i dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  8. Garon EB, Johnson ML, Lisberg AE, et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-PanTumor01 study. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract LBA49.
  9. Ahn M, Lisberg AE, Paz-Ares L, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA12.
  10. Paz-Ares L, Ahn M, Lisberg AE, et al. TROPION-Lung05: datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 1314MO.
  11. Lisberg A, Ahn M-J, Kitazono S, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2024. Abstract 8593.
  12. Goldenberg DM, Cardillo TM, Govindan SV, et al. TROP-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496-512.
  13. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987-995.
  14. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences; 2024.
  15. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-TROP-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790-2797.
  16. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746-756.
  17. Paz-Ares L, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): primary results from the phase 3 EVOKE-01 study. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2024. Abstract LBA8500.
  18. Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;[Epub ahead of print].
  19. Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today (Barc). 2019;55:575-585.
  20. Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2022;12:951589.
  21. Fang, et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9114.
  22. Cappuzzo F, Garon EB, Ahn MJ, et al. MK-2870-004: a phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations. Cancer Res. 2024;84(suppl 7):CT282.